Annual report [Section 13 and 15(d), not S-K Item 405]

INTANGIBLE ASSETS (Details Narrative)

v3.26.1
INTANGIBLE ASSETS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Oct. 12, 2018
Dec. 31, 2025
Dec. 31, 2024
Mar. 04, 2025
Accumulated amortization   $ (36,440) $ (7,352)  
Business combination, intangible assets acquired   249,500    
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]        
Patent acquired $ 15,200      
Estimated useful lives 13 years      
Trademarks [Member]        
Business combination, intangible assets acquired   249,500   $ 249,500
Customer Base [Member]        
Accumulated amortization   27,910    
Amortization expense   $ 27,910    
Estimated useful lives 13 years 10 years    
Business combination, intangible assets acquired       $ 336,200
Patents [Member]        
Amortization expense   $ 1,178 $ 1,179  
Accumulated amortization   $ 8,530